Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as alemtuzumab can locate cancer
cells and either kill them or deliver cancer-killing substances to them without harming
normal cells.
PURPOSE: Phase II trial to study the effectiveness of fludarabine followed by alemtuzumab in
treating patients who have chronic lymphocytic leukemia.